Shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) are scheduled to reverse split on Tuesday, November 24th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 23rd.
Co-Diagnostics Stock Performance
CODX stock traded down $0.04 during midday trading on Friday, reaching $0.13. The stock had a trading volume of 1,140,217 shares, compared to its average volume of 5,645,839. The stock has a market cap of $1.36 million, a PE ratio of -0.02 and a beta of 3.15. The firm has a fifty day simple moving average of $0.70 and a two-hundred day simple moving average of $2.02. Co-Diagnostics has a 52-week low of $0.13 and a 52-week high of $13.54.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.24. The company had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.17 million. Co-Diagnostics had a negative return on equity of 322.92% and a negative net margin of 5,530.54%.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Weiss Ratings lowered shares of Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. Finally, Maxim Group upgraded shares of Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Co-Diagnostics has a consensus rating of “Hold” and a consensus price target of $45.00.
View Our Latest Research Report on CODX
Hedge Funds Weigh In On Co-Diagnostics
A hedge fund recently bought a new position in Co-Diagnostics stock. Private Advisory Group LLC purchased a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,387 shares of the company’s stock, valued at approximately $122,000. Private Advisory Group LLC owned approximately 1.07% of Co-Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 14.99% of the company’s stock.
About Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
Further Reading
- Five stocks we like better than Co-Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
